Spirulina and Sjögren's syndrome: interferon signature, glandular NOX2, NK stimulation concern

The immunopathology of Sjögren’s

Type I interferon signature: The hallmark of primary Sjögren’s (pSS) is sustained plasmacytoid dendritic cell (pDC) activation producing IFN-α and IFN-β. This interferon signature drives glandular lymphocytic infiltration, activates B cells to produce anti-Ro/SSA and anti-La/SSB autoantibodies, and recruits NK cells and cytotoxic T cells to glandular tissue. The interferon signature is present in ~70% of pSS patients and correlates with disease severity.
Glandular NOX2: Salivary and lacrimal gland epithelial cells express NOX2. Interferon signalling upregulates NOX2 in glandular epithelium; the resulting superoxide activates NF-κB and amplifies pro-inflammatory cytokine production (IL-6, BAFF). BAFF (B-cell activating factor) is a key driver of the autoantibody response in pSS — it is the target of belimumab. NOX2 inhibition may reduce this amplification loop.
The NK paradox in Sjögren’s: NK cells contribute to both the pathological glandular infiltrate in pSS and to normal immunosurveillance. Spirulina stimulates NK cells and induces IL-12. In active pSS on immunosuppression, this is a concern. In mild, non-immunosuppressed Sjögren’s, the picture is less clear — but rheumatologist involvement is always appropriate before starting spirulina in any autoimmune condition.

Xerostomia (dry mouth) impairs taste, chewing, and swallowing. Spirulina powder in smoothies or blended food avoids the challenge of tablets or capsules that are difficult to swallow in the context of reduced saliva. For pSS patients: powder format is strongly preferred.
Dry eye disease (keratoconjunctivitis sicca) in pSS involves lacrimal gland NOX2 and oxidative damage to corneal epithelium. Omega-3 fatty acids are evidence-based for dry eye management. GLA (from spirulina, via the omega-6 pathway) competes with arachidonic acid at 5-LOX, producing less leukotriene-mediated ocular surface inflammation.
Iron: pSS carries a significant risk of iron deficiency anaemia due to the chronic inflammatory state (hepcidin-driven functional restriction) and reduced dietary intake from GI discomfort. Use transferrin saturation, not ferritin alone, to assess iron status in active pSS.

Hydroxychloroquine (HCQ) is standard first-line treatment in pSS for fatigue, arthralgias, and glandular function. It inhibits TLR7/9 signalling in pDCs, reducing the interferon signature. No CYP pharmacokinetic interaction with spirulina. HCQ reduces the TLR-to-interferon pathway; spirulina’s NOX2 inhibition addresses the downstream NF-κB amplification loop. These are complementary mechanisms at different points.

Muscarinic agonists used for xerostomia. No interaction with spirulina. GI side effects of pilocarpine (nausea, increased secretions) may be additive with spirulina’s minor GI polysaccharide effects at initiation. Take spirulina at a separate time from pilocarpine dosing if GI sensitivity is present.

Rituximab depletes B cells and is used in severe pSS with vasculitis, peripheral neuropathy, or cryoglobulinaemia. Spirulina’s NK stimulation requires specialist discussion before concurrent use — as in all anti-CD20 therapy contexts.

Used in pSS-associated inflammatory arthritis. No pharmacokinetic interaction with spirulina. Spirulina’s folate (~25–40 µg/5 g) contributes negligibly to folate supplementation alongside standard 5 mg folinic acid supplementation used with methotrexate.

Sjögren’s on immunosuppression (rituximab, mycophenolate, high-dose corticosteroids): discuss NK stimulation with rheumatologist before starting
Sjögren’s on HCQ only (mild, no systemic involvement): lower risk; 3–5 g/day; start slowly; discuss with rheumatologist
Use powder format in smoothies or blended food — tablets are difficult with xerostomia
Iron: assess with transferrin saturation, not ferritin alone, given the chronic inflammatory state
GLA pathway via spirulina may support dry eye management alongside topical and omega-3 treatments